Bolt Biotherapeutics (NASDAQ:BOLT) Announces Earnings Results, Meets Estimates

Bolt Biotherapeutics (NASDAQ:BOLT) issued its earnings results on Monday. The company reported ($0.38) EPS for the quarter, meeting the consensus estimate of ($0.38), Zacks reports. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Bolt Biotherapeutics Trading Down 0.3 %

Shares of BOLT traded down $0.00 during trading hours on Monday, reaching $0.44. The stock had a trading volume of 97,537 shares, compared to its average volume of 170,092. The company has a market cap of $16.75 million, a P/E ratio of -0.26 and a beta of 0.94. Bolt Biotherapeutics has a 52 week low of $0.38 and a 52 week high of $1.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average of $0.48 and a 200 day moving average of $0.56.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.